To compare the efficacy and safety of topical trifarotene cream versus adapalene gel in mild to moderate acne vulgaris

A randomized control trial to compare the efficacy and safety of topical trifarotene 0.005 percent cream versus adapalene 0.1 percent gel in mild to moderate acne vulgaris - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/077692

Enrollment

126

Registered

2024-12-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: topical cream: Topical creams will be applied topically daily once a day for 12 weeks . Results will then be compared with baseline. Control Intervention1: Topical cream- Adapalene (gro

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients aged from 10 to 50 years with active acne willing to come for regular follow up 2.No history of topical treatments for two weeks, dermatologic procedures such as laser therapy, deep chemical peeling for four weeks, systemic medications like corticosteroids, antibiotics, or spironolactone for four weeks; and 12 weeks for oral retinoids/isotretinoin, cyproterone acetate, and immunomodulators when enrolled in the study 3.Patients with facial and truncal acne defined by Investigator’s Global Assessment (IGA) score of 1 to 3 (mild to moderate)

Exclusion criteria

Exclusion criteria: 1.Patients with facial and truncal acne defined by Investigator’s Global Assessment (IGA) score of 4 (severe) 2.Acne conglobates, acne fulminans, secondary acne, drug induced acne, nodulocystic acne, or acne requiring systemic treatment 3.= 3 excoriated lesions 4.Pregnant or lactating women or plan to conceive during study period 5.Known or suspected allergies to study drugs 6.Any concomitant skin conditions over the face 7.Immunosuppressed patients

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of topical trifarotene 0.005% cream versus adapalene 0.1% gel in mild to moderate acne vulgaris.Timepoint: one year	—

Secondary

Measure	Time frame
To evaluate the safety profile of topical trifarotene 0.005% cream versus adapalene 0.1% gel in mild to moderate acne vulgaris.Timepoint: one year	—

Countries

India

Contacts

Public ContactDr E Sushnitha Johnson

Jawaharlal Nehru Medical College, Belgaum

sharada24101992@gmail.com8971670453

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026